Cannabis-associated arteritis patients with critical leg ischemia responded to conservative treatment, but few quit smoking

Among 23 patients with thromboangiitis obliterans or cannabis-associated arteritis causing critical leg ischemia, conservative treatment with iloprost and blood thinners improved symptoms in all patients, though only 13% achieved smoking abstinence.

Galyfos, George et al.·VASA. Zeitschrift fur Gefasskrankheiten·2017·Preliminary EvidenceCase Report
RTHC-01385Case ReportPreliminary Evidence2017RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Case Report
Evidence
Preliminary Evidence
Sample
N=23

What This Study Found

Over six years, 23 patients (15 with thromboangiitis obliterans and 8 with cannabis-associated arteritis) presented with critical lower limb ischemia. None had risk factors other than smoking. All patients presented with rest pain, and 12 had ulcers or necrotic lesions.

Conservative treatment (28 days of intravenous iloprost plus bemiparin, followed by oral aspirin plus cilostazol) improved clinical symptoms and ankle-brachial index in all patients (from 0.46 to 0.54, p<0.05). During follow-up, only 3 patients required bypass surgery and 2 underwent major amputation.

However, the smoking abstinence rate was very low at 13%, a critical concern since cessation is the most important factor in preventing disease progression.

Key Numbers

23 patients (15 TAO, 8 CAA). Mean ABI: 0.46 at presentation, 0.54 after 28 days (p<0.05). 3 bypass surgeries, 2 major amputations during follow-up. Smoking abstinence: 13%. 12 patients with ulcers or necrotic lesions at presentation.

How They Did This

Retrospective evaluation of patients with TAO or CAA presenting with critical limb ischemia between 2011 and 2016 at a single center. Patients requiring primary intervention were excluded. Outcomes included symptom recession, ABI improvement, lesion healing, amputation, revascularization, and abstinence rates.

Why This Research Matters

Cannabis-associated arteritis (CAA) is an under-recognized vascular condition that can lead to limb loss in young people. This study shows that conservative treatment can avoid amputation in most patients, but the dismal 13% smoking cessation rate threatens long-term outcomes and highlights the addictive nature of cannabis and tobacco co-use.

The Bigger Picture

Cannabis-associated arteritis mimics Buerger's disease (thromboangiitis obliterans) and can cause severe limb ischemia in young patients. As cannabis use increases, clinicians should be aware that cannabis, like tobacco, can cause arterial disease. The very low abstinence rate in this cohort is a sobering reminder of how difficult cessation is even when limb loss is at stake.

What This Study Doesn't Tell Us

Small retrospective case series from a single center. No control group. TAO and CAA were analyzed together, though they may have different pathophysiology. Follow-up duration was not specified in the abstract. The low abstinence rate limits interpretation of long-term outcomes.

Questions This Raises

  • ?Is CAA mechanistically different from tobacco-related TAO?
  • ?Would more aggressive smoking cessation interventions improve outcomes?
  • ?Does the type of cannabis consumed (smoked vs other) affect arteritis risk?

Trust & Context

Key Stat:
Only 13% smoking abstinence despite risk of limb loss from cannabis/tobacco arteritis
Evidence Grade:
Small retrospective case series. Provides treatment outcome data but limited by small sample and lack of controls.
Study Age:
Published in 2017. Cannabis-associated vascular disease is an emerging area of clinical awareness.
Original Title:
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Published In:
VASA. Zeitschrift fur Gefasskrankheiten, 46(6), 471-475 (2017)
Database ID:
RTHC-01385

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Describes what happened to one person or a small group.

What do these levels mean? →

Frequently Asked Questions

Can cannabis cause arterial disease?

Yes. Cannabis-associated arteritis (CAA) is a recognized condition where cannabis smoking contributes to inflammation and narrowing of arteries, particularly in the legs. It resembles Buerger's disease and can lead to critical ischemia and limb loss in young people.

Why is the abstinence rate so low?

Only 13% of patients stopped smoking despite facing potential limb loss. This reflects the powerful addictive properties of both cannabis and tobacco, which are often used together. Effective cessation support is critical for these patients but clearly challenging.

Read More on RethinkTHC

Cite This Study

RTHC-01385·https://rethinkthc.com/research/RTHC-01385

APA

Galyfos, George; Kerasidis, Stavros; Kastrisios, Georgios; Giannakakis, Sotirios; Sachmpazidis, Ioannis; Anastasiadou, Christiana; Geropapas, Georgios; Papapetrou, Anastasios; Papacharalampous, Gerasimos; Maltezos, Chrisostomos. (2017). Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.. VASA. Zeitschrift fur Gefasskrankheiten, 46(6), 471-475. https://doi.org/10.1024/0301-1526/a000649

MLA

Galyfos, George, et al. "Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.." VASA. Zeitschrift fur Gefasskrankheiten, 2017. https://doi.org/10.1024/0301-1526/a000649

RethinkTHC

RethinkTHC Research Database. "Conservative treatment of patients with thromboangiitis obli..." RTHC-01385. Retrieved from https://rethinkthc.com/research/galyfos-2017-conservative-treatment-of-patients

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.